2024 World Conference on Lung Cancer (WCLC) - Posters-P2.10B.05 Renal Toxicity in Patients with Non-Small Cell Lung Cancer Receiving Maintenance Therapy with Pemetrexed and Pembrolizuma

P2.10B.05 Renal Toxicity in Patients with Non-Small Cell Lung Cancer Receiving Maintenance Therapy with Pemetrexed and Pembrolizuma

Back to course

Pdf Summary

The study examines renal toxicity rates in patients with metastatic non-small cell lung cancer (NSCLC) receiving maintenance therapy with pemetrexed, pembrolizumab, or a combination of both. Conducted at the University of Colorado School of Medicine, it reviewed data from 149 patients who had undergone four cycles of platinum-based chemotherapy with 47 receiving pemetrexed, 77 receiving pemetrexed plus pembrolizumab, and 25 receiving pembrolizumab alone.<br /><br />The study found similar rates of renal toxicity among the different treatment groups. The analysis showed that up to 30% of patients experienced any renal event or abnormal kidney function results, with no statistically significant differences among the groups. Specifically, no significant differences were found between the groups in instances of acute kidney injury or chronic kidney disease. The rates of treatment-related renal events led to the discontinuation of pemetrexed in up to 88% of affected patients when used alone and 57% when used in combination. Pembrolizumab discontinuation due to renal events was also observed, affecting 67% of patients receiving pembrolizumab alone and 52% when in combination.<br /><br />Patient demographics included a median age of 66 to 68 years, and the study groups were diverse, although predominantly white. Co-morbidities such as chronic kidney disease, diabetes, and hypertension were present in the patient population but remained statistically similar across the treatment groups.<br /><br />Overall, the research indicates that while renal toxicity is a concern in patients undergoing these therapies, the rates are consistent across different treatment regimens with pemetrexed and pembrolizumab, suggesting that patient monitoring for renal events is crucial irrespective of the maintenance therapy administered.

Asset Subtitle

Urs Weber

Meta Tag

Speaker Urs Weber

Topic Metastatic NSCLC – Cytotoxic Therapy

Keywords

renal toxicity

metastatic NSCLC

pemetrexed

pembrolizumab

maintenance therapy

University of Colorado

acute kidney injury

chronic kidney disease

platinum-based chemotherapy

treatment discontinuation